Galectin-3 in acute coronary syndrome

Area of Science:

• Cardiology
• Biomarkers
• Clinical Research

Background:

• Acute coronary syndrome (ACS) is a leading cause of global hospitalizations.
• Biomarkers are crucial for diagnosing, stratifying risk, and predicting prognosis in cardiovascular diseases like ACS.
• Troponin is the current gold standard for ACS diagnosis, but research seeks additional prognostic markers.

Purpose of the Study:

• To review existing literature on the prognostic role of Galectin-3 (Gal-3) in patients with ACS.
• To evaluate Gal-3 as a potential predictive biomarker for adverse outcomes following ACS.

Main Methods:

• Literature review of experimental and clinical studies.
• Analysis of data on Gal-3's association with mortality and heart failure (HF) in ACS patients.

Main Results:

• Galectin-3 (Gal-3) has emerged as a significant prognostic marker in the context of ACS.
• Experimental and clinical data suggest Gal-3 plays a key role in inflammation and fibrosis.
• Gal-3 has been identified as an independent predictor of all-cause mortality, cardiovascular death, and HF occurrence post-ACS.

Conclusions:

• Galectin-3 is a promising prognostic biomarker for patients experiencing acute coronary syndrome.
• Gal-3's involvement in inflammatory and fibrotic pathways supports its predictive value for adverse cardiovascular outcomes.
• Further investigation into Gal-3 may enhance risk stratification and management strategies for ACS patients.